SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
INVA

Innoviva, Inc. (NASDAQ:INVA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$18.41+$0.00 (+0.00%)
 
Market cap
$1.31B
Insider Score
Health Score
Analyst consensus
Listed since
Oct 5, 2004
Website
Market Cap$1.31B-13.5%
Revenue (ttm)$441.75M+13.7%
Net Income$193.44M+51.9%
EPS$1.99+47.4%
Shares Out71.08M
PE Ratio7.25
Forward PE8.94
Dividendn/a
Ex-Dividend DateSep 8, 2015
Volume1,146,551
Open$18.42
Previous Close$18.41
Day's Range$18.33 - $18.70
52-Week Range$18.19 - $25.15
Beta0.33
AnalystsBuy
Price Target$31.50(+71.10%)
Earnings DateFeb 24, 2027

About INVA

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

Address
1350 Old Bayshore Highway, Burlingame, CA, 94010, US
Market Cap
1.31 billion
Employees
159
Industrial Classification
Biotechnology

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $30.50 (+65.7%)

1 firm rating INVA in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From INVA’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+0.00%
5 Days
-3.51%
1 Month
-12.58%
6 Months
-18.03%
1 Year
-13.53%

$INVA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in INVA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by INVA's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

INVA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New INVA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to INVA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in INVA

IJRiShares Core S&P Small-Cap ETF$80.10M
AFTYPacer CSOP FTSE China A50 ETF$55.51M
VTIVanguard Morningstar Total Stock Market ETF$37.32M
IWMiShares Russell 2000 ETF$36.83M
VBVanguard Morningstar Small-Cap ETF$32.58M
DFSVU.S. Small Cap Value Portfolio ETF Class Shares$26.42M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from INVA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
85
News & Sentiment
38% of score
72

News check: Piper Sandler initiated coverage with Overweight rating and $29 price target; valuation analysis pieces suggest stock appeal despite quarterly loss.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PJPInvesco Pharmaceuticals ETF2.68%
SIXSETC 6 Meridian Small Cap Equity ETF2.02%
XPHState Street SPDR S&P Pharmaceuticals ETF1.79%
HSMVFirst Trust Horizon Managed Volatility Small/Mid ETF1.02%
ECMLEuclidean Fundamental Value ETF0.97%
FSGSFirst Trust SMID Growth Strength ETF0.90%
FSCSFirst Trust SMID Capital Strength ETF0.88%
SCOWPacer Funds Trust - Pacer S&P SmallCap 600 Quality FCF Aristocrats ETF0.84%
PSCHInvesco S&P SmallCap Health Care ETF0.72%
GRPZInvesco S&P SmallCap 600 GARP ETF0.65%
FYTFirst Trust Small Cap Value AlphaDEX Fund0.54%
QQQSInvesco NASDAQ Future Gen 200 ETF0.51%

Weight is the stock’s share of each fund’s holdings.